cells result in durable engraftment after transplantation.
4-6
In myeloma, tumor contamination appears to be less freMultivariate analysis revealed that cyclophosphamide and G-CSF priming before collection of hematopoietic quent in peripheral blood stem cells compared with bone marrow in the same patient. 7 In most but not all cases, precursors (P Ͻ 0.001) was a positive predictor of rapid engraftment and prior exposure to melphalan given unmanipulated peripheral blood stem cell products are preferable to bone marrow harvests as a method of reducing orally (P = 0.02) was a negative predictor of subsequent platelet engraftment. The number of mononuclear cells myeloma autograft tumor contamination. 8 For these reasons, mobilized blood stem cell transplants have largely collected, the patient's disease status at the time of transplant and the presence of circulating plasma cells replaced autologous bone marrow transplants for multiple myeloma. in the harvested product did not have a significant impact on time to platelet engraftment. We conclude
The median time to achieve sustained platelet counts greater than 50 × 10 9 /l has been reported to be as short as that cyclophosphamide and G-CSF priming shortened the time to achieve platelet engraftment compared with 15 days after peripheral blood stem cell transplantation. 9 Others have demonstrated a reduced ability to mobilize pro-G-CSF alone. Prior exposure to melphalan delayed platelet engraftment and can lead to complete failure of genitors in patients who have myeloma compared with those who have lymphoma. 10 Moreover, complete failure platelet recovery. Stem cells should be collected before melphalan administration in patients with multiple of platelet recovery has been reported, and some patients have taken in excess of 50 days to achieve a platelet count myeloma who are candidates for possible blood cell transplantation.
of 20 × 10 9 /l. 11 We also have encountered patients undergoing peripheral Keywords: hematopoietic stem cell; leukapheresis; melphalan; multiple myeloma; stem cell transplantation blood stem cell transplantation for multiple myeloma who experienced delayed or inadequate platelet engraftment. Failure of platelet recovery is rarely seen in our larger group of patients undergoing peripheral blood stem cell Myeloablative chemotherapy with infusion of hematopotransplantation for recurrent malignant lymphoma. We ietic precursors, capable of reconstituting marrow function, undertook the current study to determine if there are clinical is applied increasingly in the primary management of predictors for the risk of poor platelet recovery in patients patients with multiple myeloma. Initially, autologous bone who receive transplants for multiple myeloma. marrow was reinfused with up to 30% plasma cells with excellent reconstitution of hematopoietic function.
1 It was subsequently demonstrated that there are circulating hemaMaterials and methods topoietic progenitor cells that can be collected and these . Forty-eight of the Thirty-one patients received G-CSF priming (Table 1) , 5 g/kg subcutaneously daily, until the completion of periph-51 received radiation and three received conditioning with non-radiation-containing regimens. eral blood stem cell collection. For patients receiving G-CSF alone, stem cell apheresis was begun on the fifth day following G-CSF initiation.
Patient population
Definition of engraftment Cyclophosphamide priming was added in June 1994.
12,13
The 12 patients who received cyclophosphamide priming All patients had the following measurements taken on a daily basis for the first 30 days after stem cell infusion: were given 1.5 g/m 2 over 60 min daily for 2 consecutive days. The dose of cyclophosphamide was selected to obviwhite blood cell count, absolute neutrophil count, and platelet count. From day +30 to day +100, the counts were measate the need for uroprophylaxis. An attempt was made to have the entire collection procedure be performed as an ured at a minimum of once weekly. The definition of granulocyte engraftment was the first day of 3 consecutive outpatient procedure. To minimize the period of severe granulocytopenia, a dose of 1.5 g/m 2 × 2 days was selected.
days in which the absolute neutrophil count exceeded 0.5 × 10 9 /l. Platelet engraftment was considered the first Following cyclophosphamide, G-CSF was begun on day 3. Stem cell apheresis began when the total white cell count day of 3 consecutive days in which the platelet count untransfused exceeded 50 × 10 9 /l. recovered to greater than 500/l. Of the 12 patients, five required platelets during collection.
Ten liters of blood were processed with each leukapherStatistical analysis esis collection. The target progenitor cell number was 8 × 10 8 mononuclear cells/kg in 47 of the patients. This All patients were assessed at day +100 for graft function. At day +100, patients who did not fulfill these criteria were goal was achieved in 42 of the 47, with the remaining five collecting 7.7, 7.4, 6.9, 6.8 and 3.8 × 10 8 mononuclear censored as graft failures. All patients who died before day +100 who failed to achieve engraftment as defined above above as well as the two patients who had granulocyte engraftment after day +100. Of the nine remaining patients, were censored on the date of death. No patients were excluded from analysis. Graft function analysis was perforthree represent early deaths before platelet engraftment but after granulocyte engraftment and six were true failures of med using the Kaplan-Meier method. Multivariate analysis was performed using the proportional-hazards model (Cox).
platelet recovery in spite of survival beyond day +100. all 51 patients. There is a steeply sloped portion of the curve from day +7 until day +18 that reflects a subset of patients with rapid platelet engraftment. After day +20, the Results curve levels out, indicating delayed platelet recovery for roughly half of the patients. A total of 51 patients had transplants, and their characteristics are given in Table 1 . At the time of pretransplant
In vitro measurement of granulocyte-macrophage colony-forming units (GM-CFU) was performed in 35 of the evaluation, the median percentage of bone marrow plasma cells was 34%, with 54% of the population having greater 51 patients. The number of GM-CFU/kg body weight was associated with rapid platelet recovery (P Ͻ 0.001). than 30% bone marrow plasma cells. The bone marrow labeling index ranged from 0 to 7.4%, with a median of Because of the large number of missing observations, the number of GM-CFU was not included in the multivariate 0.9%; 56% had a labeling index greater than 0.8%. Fortysix of the patients underwent melphalan total body analysis of clinical factors used to predict platelet recovery. A univariate analysis was undertaken using the factors irradiation (TBI)-based conditioning, two patients received cyclophosphamide and TBI, and three patients who had in Table 2 to assess their impact on graft function. Five factors were significant in predicting time to platelet extensive prior radiation treatment received non-radiationcontaining regimens.
engraftment in the univariate model. When these factors were placed into a proportional-hazards multivariate model, Of the 51 patients, nine received transplants after fewer than 8 × 10 8 mononuclear cells/kg were collected. Two of only two factors remained predictive of time to platelet engraftment. Only cyclophosphamide and G-CSF-primed these patients were considered graft failures, not achieving 50 × 10 9 platelets/l by day 100. The median time to platelet harvests (P Ͻ 0.001) and melphalan given before stem cell collection (P = 0.02) were statistically significant predictors recovery in these nine patients was 28 days. All patients received G-CSF, 5 g/kg per day subcutaneously, beginof graft function. Although melphalan was statistically significant as a conning on day +1. The median time to achieve an absolute neutrophil count greater than 0.5 × 10 9 /l was 10.5 days.
tinuous variable, it was also assessed as a categorical variable to determine whether a threshold existed for melphalan Three patients died not having achieved an absolute neutrophil count of 0.5 × 10 9 /l. One patient died on day −1 of uncontrolled sepsis, one died on day +12 of veno-occlusive Table 2 Univariate analysis of impact of variables on platelet disease of the liver, and one patient died on day +49 of engraftment adult respiratory distress syndrome and pulmonary aspergillosis. There were two patients who achieved an absolute Variable P value neutrophil count greater than 0.5 × 10 9 /l after day +100 (day 174 and day 199). number of GM-CFU (35 patients) and the total cumulative melphalan dose before stem cell collection. There was a correlation with Spearman rho of −0.57 (P = 0.001).
Discussion
Our data indicate that cyclophosphamide plus G-CSF priming before collection of circulating progenitors and avoidance of melphalan are important to collect adequate progenitors to prevent delay or failure of platelet engraftment after transplantation in multiple myeloma patients. In previously untreated patients who survive the early post-trans- 14 It has been (Ͼ50 × 10 9 /l) in those patients receiving no prior melphalan (n = 14) comsuggested that higher progenitor cell yields occur with pared with those receiving any prior melphalan (n = 37).
higher priming doses of growth factor. G-CSF at 10 g/kg provided a higher yield than a combination of cyclophosphamide priming with a growth factor dose of 5 g/kg.
15 exposure. Figure 2 illustrates time to platelet engraftment However, because none of our patients received a dose of in those patients who had received no melphalan compared G-CSF greater than 5 g/kg, it is impossible to make a with those who had received any exposure to melphalan direct comparison. Others have suggested that combibefore stem cell collection. The median time to platelet nations of growth factors, including G-CSF and GM-CSF, engraftment was 14 days vs 50 days (P Ͻ 0.001). All enhance the mobilization of hematopoietic precursors withpatients who had not previously received melphalan had out pulsed chemotherapy. 16 In one study, higher peak engraftment by day +63, whereas more than one-third of values for CD34 + were seen in patients receiving 7 g/m 2 the patients who had melphalan exposure still had not of cyclophosphamide compared with 4 g/m 2 of cyclophosachieved 50 × 10 9 platelets/l by day +100. An identical phamide. 17 Even under these circumstances, mobilization analysis was performed on those patients receiving Ͻ200
in myeloma patients was unreliable; poor yields were seen mg total dose melphalan compared with those receiving in patients with the heaviest bone marrow infiltration with Ͼ200 mg (Figure 3) . The median time to platelet plasma cells. 12 There appears to be no difference between engraftment was significantly different: 15 days vs 100 days GM-CSF and G-CSF in terms of the ability to mobilize (P Ͻ 0.001). In the group of patients given Ͼ200 mg of sufficient numbers of hematopoietic precursors. 18 It is genmelphalan, only one-third had achieved 50 × 10 9 platelets/l erally agreed, however, that growth factors are needed to by day +100. Analysis was also undertaken for a melphalan reduce the number of collections required to perform safe dose of 100 mg. There were 32 patients who received Ͼ100 autografting. 13, 19, 20 mg melphalan. Median time to 50 × 10 9 platelets/l was 60 Hematopoietic recovery has been correlated with the days. Nineteen patients received Ͻ100 mg of melphalan dose of GM-CFU or CD34 + cells. 21 A correlation between before a peripheral blood stem cell collection, with median the number of CD34 + cells and GM-CFU has been reported, time for platelet engraftment of 14.5 days (P = 0.0003).
suggesting one can serve as a surrogate measure of the The risk of graft failure appears to be minimal in patients other. 22 Patients receiving fewer than 2 × 10 6 CD34 + whose prior melphalan exposure did not exceed 200 mg. cells/kg have been reported to have significantly prolonged A Spearman rank correlation was performed on the platelet recovery. 23 The absolute number of CD34 cells in the leukapheresis product has previously 11 been correlated with exposure to prior treatment. Measures of GM-CFU are not available in many clinical laboratories that perform blood cell transplants. Standardization between laboratories has not been perfected, and there is a time delay to allow for colony growth, so that immediate results are not available.
Most clinical centers prospectively determine the adequacy of collection based on the number of collected mononuclear cells and not on CD34 or GM-CFU counts. In our study we could not conclude that the number of mononuclear cells collected correlated with engraftment. However, since there was a minimum threshold set for each patient, and this threshold was achieved in 90%, it would and collection technique selection. 24 Although graft funcmg (n = 29) compared with those whose prior melphalan exposure was Ͼ200 mg (n = 22).
tion correlates well with the total number of CD34 + cells or GM-CFU infused, 25, 26 difficulty with standardizing assays Prince et al 42 assessed myeloma patients undergoing stem cell transplant and found that extensive prior melmakes it hard to establish an appropriate threshold. Moreover, some authors have found no correlation between phalan therapy resulted in a high incidence of delayed engraftment. We continue to see patients referred for con-CD34 + content and GM-CFU. 27 There are also those who have not been able to demonstrate a correlation between sideration of transplant after 6 to 12 months of melphalanbased therapy, suggesting that nontransplant oncologists are GM-CFU infused and the time to achieve a platelet count of 50 × 10 9 /l. 28 Without a good in vitro measure for predicting not fully aware of the toxic effect of melphalan on stem cells. platelet recovery, clinical factors associated with durable engraftment become important.
In conclusion, platelet engraftment is problematic in patients with multiple myeloma following blood cell transWhy does melphalan therapy appear to have such a profound effect on graft function? The leukemogenic effect of plantation. The kinetics of the late engraftment suggest inadequate collection of progenitor cells with standard leumelphalan in multiple myeloma and ovarian cancer is well recognized, reflecting its damaging effect on hematopoietic kapheresis techniques. There is a need for clinical predictors of engraftment because of delays involved in acquiring stem cells. 29, 30 Lymphoma patients exposed to the related alkylator cyclophosphamide as part of cyclophosphamide, GM-CFU quantification and the lack of standardization among laboratories. Our clinical analysis suggests that melhydroxydaunomycin, vincristine (Oncovin), and prednisone (CHOP) chemotherapy have a low risk of graft failure. One phalan delays engraftment. It likely decreases the number of viable progenitors collected. Stem cells are best acquired possibility is that the oral mode of administration of melphalan results in greater cumulative toxic effect on the stem before any exposure to melphalan-based chemotherapy, and priming with both cyclophosphamide and G-CSF enhances cells. Melphalan, when administered intravenously, has a relatively short half-life (17-75 min) and a brief area under the likelihood of subsequent rapid engraftment. the curve. 31 Kinetics of melphalan given orally are far different, with most patients receiving four daily doses each month or seven daily doses every 6 weeks. 32 This results Acknowledgements in a much greater cumulative area under the curve. 33 It also failure. 14 
